• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
IMM 2.54% 30.3¢

IMMUTEP LIMITED

Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company... Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Latest Threads

Tag Subject Date Created with Sketch. Comments Created with Sketch. Views Created with Sketch.
IMM
News: IMM Immutep Announces Positive Feedback Received From US FDA
11:45 0 1
11:45 Last post  Hot News Comments Created with Sketch.  0  Views Created with Sketch.  1 
IMM 11:18 5 1.3K
11:18 Last post  theoc Comments Created with Sketch.  5  Views Created with Sketch.  1.3K 
IMM
Media
2
20/07/24 99 45K
20/07/24 Last post  Joe007 Comments Created with Sketch.  99  Views Created with Sketch.  45K 
IMM
Overnight Market report
45 46 47
20/07/24 2.8K 1.1M
20/07/24 Last post  ahjay Comments Created with Sketch.  2.8K  Views Created with Sketch.  1.1M 
IMM 19/07/24 10 4.6K
19/07/24 Last post  Bylosellhi Comments Created with Sketch.  10  Views Created with Sketch.  4.6K 
IMM
News: IMM Immutep Receives Regulatory Clearance for Phase I Study of First-in-Class LAG-3 Agonist...
17/07/24 0 270
17/07/24 Last post  Hot News Comments Created with Sketch.  0  Views Created with Sketch.  270 
IMM 16/07/24 37 19K
16/07/24 Last post  hanshenlo99 Comments Created with Sketch.  37  Views Created with Sketch.  19K 
IMM 12/07/24 0 666
12/07/24 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  666 

See All Discussions arrow Created with Sketch.

Timeline

Successful Meeting with FDA on Phase III Design in NSCLC
22 Jul 08:12
 
Regulatory Clearance received for Phase 1 trial of IMP761
17 Jul 08:48
 
Becoming a substantial holder
12 Jul 15:51
 
Positive results in TACTI-003 for 1L HNSCC cohort B patients
12 Jul 08:26
 
Webcast to discuss data presented at ESMO Plenary Session
12 Jul 08:26
 
Change in substantial holding
04 Jul 08:16
 
View More arrow Created with Sketch.
(20min delay)
Last
30.3¢
Change
0.008(2.54%)
Mkt cap ! $439.4M
Open High Low Value Volume
30.0¢ 30.5¢ 30.0¢ $132.1K 436.7K

Buyers (Bids)

No. Vol. Price($)
17 374343 30.0¢
 

Sellers (Offers)

Price($) Vol. No.
30.5¢ 181014 11
View Market Depth
Last trade - 11.24am 22/07/2024 (20 minute delay) ?
Last
30.5¢
  Change
0.008 ( 3.25 %)
Open High Low Volume
30.5¢ 30.5¢ 30.0¢ 163093
Last updated 11.26am 22/07/2024 ?
IMM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.